Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
LifeMD, Inc. (NASDAQ: LFMD) reported Q1 2021 revenues of $18.2 million, a 323% increase from $4.3 million in Q1 2020. Subscription revenue surged to 92% of total revenue, up from 75% the previous year. Telehealth orders grew 373% to 164,452. Gross profit increased 403% to $14.9 million, achieving a gross margin of 82%. Operating expenses rose to $26.8 million, leading to a net loss of $11.6 million. Cash on hand reached $13.4 million, bolstered by a private placement. The company raised its full-year revenue guidance to $90-$100 million, reflecting strong growth prospects.
LifeMD, Inc. (NASDAQ: LFMD) will host a conference call on May 13, 2021 at 4:30 p.m. ET to discuss its unaudited financial results for the first quarter of fiscal 2021. The call will follow the release of the financial results and is open to all investors. LifeMD operates as a direct-to-patient telehealth company, providing virtual medical treatment, prescription medications, and over-the-counter products to patients nationwide.
For participation, please call 5 minutes before the start time using the toll-free number provided.
LifeMD, Inc. (NASDAQ: LFMD) reported expected record revenue of $18.2 million for Q1 2021, exceeding its prior guidance of $17 million. This marks a 323% increase year-over-year and a 41% rise from the previous quarter. Strong retention and patient acquisition led to a 373% growth in telehealth order volume. Subscriptions accounted for 92% of Q1 revenue, up from 75% the previous year, driven by sales of Shapiro MD™ and Rex MD™ products. The company also launched NavaMD™, a teledermatology service, enhancing its market portfolio.
LifeMD, Inc. (NASDAQ: LFMD) has issued a response to a damaging report from anonymous short-seller Culper Research, citing numerous inaccuracies. The company emphasizes its commitment to transparency and patient care, outlining its quality controls and physician vetting processes. CEO Justin Schreiber criticized the credibility of Culper’s claims, specifically regarding LifeMD's licensing practices and operational integrity. LifeMD aims for a complete transition to its digital health platform, Veritas MD, by Q2 2021. The company affirms its robust telehealth infrastructure and dedication to shareholder trust.
LifeMD (NASDAQ: LFMD) recently addressed false claims posted about the company and its executives by a purported research firm. The company maintains it has had no contact with this firm and is taking legal action with its counsel, Quinn Emanuel Urquhart & Sullivan, LLP, to investigate the source of the claims. LifeMD has stated its commitment to transparency and compliance, urging anyone with information to contact them. The company stands by its regulatory disclosures and reassures stakeholders of its operational integrity.
LifeMD, Inc. (NASDAQ: LFMD) has launched NavaMD, a tele-dermatology brand, expanding its portfolio into the growing $40 billion telehealth market. The service offers personalized dermatology care across all 50 states, focusing on conditions like acne and rosacea. This brand is the third successful launch in four years, aimed at acquiring female patients through targeted marketing. NavaMD combines telemedicine with proprietary skincare products licensed from Restorsea, enhancing its treatment offerings. The approach promotes recurring revenues and shareholder value through a user-friendly, three-step customer journey.
LifeMD, Inc. (NASDAQ: LFMD) reported impressive financial results for 2020, with revenue soaring 199% to $37.3 million. In Q4 2020, revenue reached $12.9 million, a 227% increase year-over-year, largely driven by a 293% rise in telemedicine product sales. The company’s annual recurring revenue (ARR) surged 443% to $53.4 million by year-end. Despite significant growth, the company recorded a net loss of $63.4 million for 2020, impacted by high operating costs. For 2021, LifeMD forecasts revenues between $85 million to $95 million.
LifeMD (NASDAQ: LFMD), a telehealth leader, is set to discuss its fourth-quarter and full-year financial results for 2020 on March 29, 2021, at 4:30 p.m. ET. An earnings press release will precede the call. Participants can join via toll-free and international numbers with a conference ID of 4067431. The call will also be available via webcast and can be replayed until April 12, 2021. LifeMD provides direct-to-patient telehealth services, enhancing healthcare accessibility with licensed providers and convenient home delivery.
LifeMD, Inc. (NASDAQ: LFMD) announced on March 16, 2021, that its Compensation Committee granted an equity award to a new employee on March 15, 2021. The award consists of options to purchase 90,000 shares of common stock at an exercise price of $19.61, equal to the stock's closing price on the grant date. The options will vest monthly over three years, contingent on the employee's continued service, and have a five-year term. This award aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
LifeMD, Inc. (NASDAQ: LFMD) has been invited to the 33rd Annual ROTH Growth Conference, taking place virtually from March 15-17, 2021. CEO Justin Schreiber, CFO Marc Benathen, and Chief Business Officer Corey Deutsch will engage with investors and analysts. A key topic will be the launch of the company’s new subscription-based primary care and concierge telehealth services, aimed at expanding its patient base. LifeMD anticipates Q1 2021 revenues to exceed $17 million, reflecting a 295% increase year-over-year, with subscriptions projected to contribute over 80% of this revenue.